Ai-Qin Song
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ai-Qin Song has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Hua Pan
Department of Pediatrics, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, China
1 shared publicationJianke Liu
Department of Pediatric Medical Center, The Affiliated Hospital of Qingdao University, Qingdao, China
1 shared publication- Jiye Song
Department of Pediatric Medical Center, The Affiliated Hospital of Qingdao University, Qingdao, China
1 shared publication Lei Chen
Department of Pediatric Hematology, Affiliated Hospital of Qingdao University, Qingdao 266003, Shandong, China
1 shared publicationLi-Rong Sun
Department of Pediatric Hematology, Affiliated Hospital of Qingdao University, Qingdao 266003, Shandong, China
1 shared publicationLiang Song
Department of Pediatrics, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, China
1 shared publication
Latest Publications
- 18 November 2026
- Published by Wiley in Clinical Genetics
Age of Onset and Genetic Factors Associated With the Cardiomyopathic Phenotype of Very Long‐Chain Acyl‐ CoA Dehydrogenase Deficiency: A Literature Review
Very long‐chain acyl‐CoA dehydrogenase deficiency (VLCADD) is an autosomal recessive disorder of mitochondrial fatty acid β ‐oxidation caused by biallelic pathogenic variants in ACADVL. Its most severe form, the cardiomyopathic phenotype, presents early, progresses rapidly, and carries high mortality; yet quantitative tools for early risk stratification are lacking. We conducted a systematic review and pooled analysis of 213 published VLCADD cases to investigate the associations of age at onset, acylcarnitine profiles, and ACADVL variant types with the cardiomyopathic phenotype. Univariate analysis showed that log‐transformed age at onset, C14 acylcarnitine levels, and variant type differed significantly between the cardiomyopathic and noncardiomyopathic groups, whereas sex and C14:1 level did not. Age at onset demonstrated excellent discriminative ability (area under the curve 0.90; optimal cutoff 5.48 months, sensitivity 88.3%, specificity 83.7%). A clear genotype–phenotype gradient was observed, with carriers of two loss‐of‐function (LOF) variants showing the highest risk. In conclusion, age at onset is the most robust and discriminative marker of the cardiomyopathic phenotype, and two LOF variants identify a high‐risk subgroup. These findings support early risk stratification and targeted cardiac surveillance in VLCADD.
- 18 November 2026
- Published by Wiley in Clinical Genetics
Age of Onset and Genetic Factors Associated With the Cardiomyopathic Phenotype of Very Long‐Chain Acyl‐ CoA Dehydrogenase Deficiency: A Literature Review
Very long‐chain acyl‐CoA dehydrogenase deficiency (VLCADD) is an autosomal recessive disorder of mitochondrial fatty acid β ‐oxidation caused by biallelic pathogenic variants in ACADVL. Its most severe form, the cardiomyopathic phenotype, presents early, progresses rapidly, and carries high mortality; yet quantitative tools for early risk stratification are lacking. We conducted a systematic review and pooled analysis of 213 published VLCADD cases to investigate the associations of age at onset, acylcarnitine profiles, and ACADVL variant types with the cardiomyopathic phenotype. Univariate analysis showed that log‐transformed age at onset, C14 acylcarnitine levels, and variant type differed significantly between the cardiomyopathic and noncardiomyopathic groups, whereas sex and C14:1 level did not. Age at onset demonstrated excellent discriminative ability (area under the curve 0.90; optimal cutoff 5.48 months, sensitivity 88.3%, specificity 83.7%). A clear genotype–phenotype gradient was observed, with carriers of two loss‐of‐function (LOF) variants showing the highest risk. In conclusion, age at onset is the most robust and discriminative marker of the cardiomyopathic phenotype, and two LOF variants identify a high‐risk subgroup. These findings support early risk stratification and targeted cardiac surveillance in VLCADD.
- Open Access
- 1 January 2023
- Published by Wiley in Analytical Cellular Pathology
- Vol. 2023 (1)
Association between CHFR and PARP‐1, and Their Roles in Regulation of Proliferation and Apoptosis of B Cell Lymphoma
Background. Aberrant methylation of checkpoint with forkhead and ring finger domains (CHFR) was found in B‐cell non‐Hodgkin lymphoma (NHL), whereas its role in carcinogenesis is not clear. CHFR can control poly (ADP‐ribose) polymerase levels by causing its degradation. The study was aimed to explore the roles and mechanisms of CHFR in the pathogenesis of B‐cell NHL. Methods. Short hairpin ribonucleic acid (ShRNAs) targeting CHFR and poly (ADP‐ribose) polymerase 1 (PARP‐1) were transduced into Raji cells, and real‐time polymerase chain reaction (PCR) and western blotting were carried out to determine their expression. Afterwards, the CCK‐8 assay and flow cytometry were used to evaluate the cell growth and apoptosis. Tumor size and weight were determined using a xenograft model, and decitabine (5‐Aza‐dC) was used to further determine the methylation status of CHFR through a methylation specificity‐PCR assay. Results. 5‐Aza‐dC‐treatment promoted the expression of CHFR and decreased the expression of PARP‐1 at both messenger ribonucleic acid (mRNA) and protein levels. 5‐Aza‐dC also accelerated Raji‐cell apoptosis and restrained its growth in vitro and in vivo (P < 0.05). These results were contrary to those observed in the shRNA‐CHFR group but consistent with those observed in the shRNA‐PARP‐1 group. The expression profiles of CHFR and PARP‐1 in the xenograft model were consistent with those in the cellular model. Treatment with 5‐Aza‐dC led to demethylation of CHFR in nude mice. Besides, there may be a negative correlation between CHFR and PARP‐1 in B‐cell NHL cells. Conclusion. Our findings indicated that 5‐Aza‐dC could lead to the demethylation of the CHFR promoter and suppress Raji cell growth.
- 1 January 2023
- Published by Wiley in Analytical Cellular Pathology
- Vol. 2023 (1)
Open AccessAssociation between CHFR and PARP‐1, and Their Roles in Regulation of Proliferation and Apoptosis of B Cell Lymphoma
Background. Aberrant methylation of checkpoint with forkhead and ring finger domains (CHFR) was found in B‐cell non‐Hodgkin lymphoma (NHL), whereas its role in carcinogenesis is not clear. CHFR can control poly (ADP‐ribose) polymerase levels by causing its degradation. The study was aimed to explore the roles and mechanisms of CHFR in the pathogenesis of B‐cell NHL. Methods. Short hairpin ribonucleic acid (ShRNAs) targeting CHFR and poly (ADP‐ribose) polymerase 1 (PARP‐1) were transduced into Raji cells, and real‐time polymerase chain reaction (PCR) and western blotting were carried out to determine their expression. Afterwards, the CCK‐8 assay and flow cytometry were used to evaluate the cell growth and apoptosis. Tumor size and weight were determined using a xenograft model, and decitabine (5‐Aza‐dC) was used to further determine the methylation status of CHFR through a methylation specificity‐PCR assay. Results. 5‐Aza‐dC‐treatment promoted the expression of CHFR and decreased the expression of PARP‐1 at both messenger ribonucleic acid (mRNA) and protein levels. 5‐Aza‐dC also accelerated Raji‐cell apoptosis and restrained its growth in vitro and in vivo (P < 0.05). These results were contrary to those observed in the shRNA‐CHFR group but consistent with those observed in the shRNA‐PARP‐1 group. The expression profiles of CHFR and PARP‐1 in the xenograft model were consistent with those in the cellular model. Treatment with 5‐Aza‐dC led to demethylation of CHFR in nude mice. Besides, there may be a negative correlation between CHFR and PARP‐1 in B‐cell NHL cells. Conclusion. Our findings indicated that 5‐Aza‐dC could lead to the demethylation of the CHFR promoter and suppress Raji cell growth.
- Open Access
- 30 April 2022
- Published by Hindawi Limited in International Journal of Genomics
- Vol. 2022, 1-18
Identification and Validation of Inflammatory Response-Related Gene Signatures to Predict the Prognosis of Neuroblastoma
Background. Neuroblastoma (NB) is the third most common malignant tumor in children. The inflammation is believed to be closely related to NB patients’ prognosis. However, there is no comprehensive research to study the role of inflammatory response-related gene (IRRG) in NB patients. Methods. We downloaded the gene expression profiles of NB patients from GEO and TARGET database, and the expression of 200 IRRGs was extracted. Then, we performed differentially analysis between INSS stage 4 and INSS stage 4S NB patients. The univariate and multivariate Cox regression analyses were performed to screen out the overall survival- (OS-) and event-free survival- (EFS-) related IRRGs in GSE49710, and two signatures were constructed; both signatures were evaluated by Kaplan-Meier (K-M) survival curve and receiver operating characteristic (ROC) curve. Finally, the TARGET cohort was used to validate IRRG signatures, and the independence of the prognostic IRRG signatures was evaluated by integrating clinical information. Results. We screened out 10 OS-related IRRGs and 11 EFS-related IRRGs. Then, we identified that OS- and EFS-related IRRG signatures and found that the OS and EFS of NB patients in the low-risk group were significantly superior than those in the high-risk group (both value < 0.0001). The AUC values of 3-, 5-, and 7-year OS are 0.910, 0.933, and 0.921, respectively, and 3-, 5-, and 7-year EFS are 0.840, 0.835, and 0.837, respectively. In addition, we found that both IRRG signatures can be used as independent prognostic indicators for patients with NB. Both IRRG signatures still have good predictive ability in validation cohort. Conclusions. We constructed and validated two prognostic gene signatures based on IRRGs. Our study helped us to better understand the role of inflammation in NB and provided new insights for the prognosis assessment and treatment strategy for NB patients.
- 30 April 2022
- Published by Hindawi Limited in International Journal of Genomics
- Vol. 2022, 1-18
Open AccessIdentification and Validation of Inflammatory Response-Related Gene Signatures to Predict the Prognosis of Neuroblastoma
Background. Neuroblastoma (NB) is the third most common malignant tumor in children. The inflammation is believed to be closely related to NB patients’ prognosis. However, there is no comprehensive research to study the role of inflammatory response-related gene (IRRG) in NB patients. Methods. We downloaded the gene expression profiles of NB patients from GEO and TARGET database, and the expression of 200 IRRGs was extracted. Then, we performed differentially analysis between INSS stage 4 and INSS stage 4S NB patients. The univariate and multivariate Cox regression analyses were performed to screen out the overall survival- (OS-) and event-free survival- (EFS-) related IRRGs in GSE49710, and two signatures were constructed; both signatures were evaluated by Kaplan-Meier (K-M) survival curve and receiver operating characteristic (ROC) curve. Finally, the TARGET cohort was used to validate IRRG signatures, and the independence of the prognostic IRRG signatures was evaluated by integrating clinical information. Results. We screened out 10 OS-related IRRGs and 11 EFS-related IRRGs. Then, we identified that OS- and EFS-related IRRG signatures and found that the OS and EFS of NB patients in the low-risk group were significantly superior than those in the high-risk group (both value < 0.0001). The AUC values of 3-, 5-, and 7-year OS are 0.910, 0.933, and 0.921, respectively, and 3-, 5-, and 7-year EFS are 0.840, 0.835, and 0.837, respectively. In addition, we found that both IRRG signatures can be used as independent prognostic indicators for patients with NB. Both IRRG signatures still have good predictive ability in validation cohort. Conclusions. We constructed and validated two prognostic gene signatures based on IRRGs. Our study helped us to better understand the role of inflammation in NB and provided new insights for the prognosis assessment and treatment strategy for NB patients.
- Open Access
- 1 January 2016
- Published by Medknow in Asian Pacific Journal of Tropical Medicine
- Vol. 9 (1) , 91-95
Effect of insulin and metformin on methylation and glycolipid metabolism of peroxisome proliferator-activated receptor γ coactivator-1A of rat offspring with gestational diabetes mellitus
To discuss the effect of insulin and metformin on a methylation and glycolipid metabolism of peroxisome proliferator-activated receptor γ coactivator-1A (PPARGC1A) of rat offspring with gestational diabetes mellitus (GDM). A total of 45 pregnant rats received the intraperitoneal injection of streptozotocin to establish the pregnant rat model of GDM. A total of 21 pregnant rats with GDM were randomly divided into three groups, with 7 rats in each group, namely the insulin group, metformin group and control group. Rats in the insulin group received the abdominal subcutaneous injection of 1 mL/kg recombinant insulin glargine at 18:00 every day. Rats in the metformin group received the intragastric infusion of metformin hydrochloride at 18:00 every day, with the first dose of 300 mg/kg. The doses of two groups were adjusted every 3 d to maintain the blood glucose level at 2.65-7.62 mmol/L. Rats in the control group received the intragastric infusion of 1 mL normal saline at 18:00 every day. After the natural delivery of pregnant rats, 10 offspring rats were randomly selected from each group. At birth, 4 wk and 8 wk after the birth of offspring rats, the weight of offspring rats was measured. The blood glucose level of offspring rats was measured at 4 wk and 8 wk, while the level of serum insulin, triglyceride and leptin was measured at 8 wk. The weight of offspring rats at birth in the insulin group and metformin group was significantly lower than the one in the control group (P < 0.05), and there was no significant difference at 4 wk and 8 wk among three groups (P > 0.05). The fasting blood glucose and random blood glucose in the insulin group and metformin group at 4 wk and 8 wk were all significantly lower than ones in the control group (P < 0.05); there was no significant difference between the insulin group and metformin group (P > 0.05). The expression of PPARGC1A mRNA in the insulin group and metformin group was significantly higher and the methylation level of PPARGC1A was significantly lower than the one in the control group (P < 0.05); but there was no significant difference between the insulin group and metformin group (P > 0.05). Insulin and leptin at 8 wk in the insulin group and metformin group were significantly higher, while triglyceride was significantly lower than the one in the control group (P < 0.05); triglyceride level in the insulin group was significantly higher than the one in the metformin group (P < 0.05). There was no significant difference in insulin and leptin level between the insulin group and metformin group (P > 0.05). GDM can induce the methylation of PPARGC1A of offspring rats to reduce the expression of PPARGC1A mRNA and then cause the disorder of glycolipid metabolism when the offspring rats grow up; the insulin or metformin in the treatment of pregnant rats with GDM can reduce the methylation level of PPARGC1A and thus improve the abnormal glycolipid metabolism of offspring rats.
- 1 January 2016
- Published by Medknow in Asian Pacific Journal of Tropical Medicine
- Vol. 9 (1) , 91-95
Open AccessEffect of insulin and metformin on methylation and glycolipid metabolism of peroxisome proliferator-activated receptor γ coactivator-1A of rat offspring with gestational diabetes mellitus
To discuss the effect of insulin and metformin on a methylation and glycolipid metabolism of peroxisome proliferator-activated receptor γ coactivator-1A (PPARGC1A) of rat offspring with gestational diabetes mellitus (GDM). A total of 45 pregnant rats received the intraperitoneal injection of streptozotocin to establish the pregnant rat model of GDM. A total of 21 pregnant rats with GDM were randomly divided into three groups, with 7 rats in each group, namely the insulin group, metformin group and control group. Rats in the insulin group received the abdominal subcutaneous injection of 1 mL/kg recombinant insulin glargine at 18:00 every day. Rats in the metformin group received the intragastric infusion of metformin hydrochloride at 18:00 every day, with the first dose of 300 mg/kg. The doses of two groups were adjusted every 3 d to maintain the blood glucose level at 2.65-7.62 mmol/L. Rats in the control group received the intragastric infusion of 1 mL normal saline at 18:00 every day. After the natural delivery of pregnant rats, 10 offspring rats were randomly selected from each group. At birth, 4 wk and 8 wk after the birth of offspring rats, the weight of offspring rats was measured. The blood glucose level of offspring rats was measured at 4 wk and 8 wk, while the level of serum insulin, triglyceride and leptin was measured at 8 wk. The weight of offspring rats at birth in the insulin group and metformin group was significantly lower than the one in the control group (P < 0.05), and there was no significant difference at 4 wk and 8 wk among three groups (P > 0.05). The fasting blood glucose and random blood glucose in the insulin group and metformin group at 4 wk and 8 wk were all significantly lower than ones in the control group (P < 0.05); there was no significant difference between the insulin group and metformin group (P > 0.05). The expression of PPARGC1A mRNA in the insulin group and metformin group was significantly higher and the methylation level of PPARGC1A was significantly lower than the one in the control group (P < 0.05); but there was no significant difference between the insulin group and metformin group (P > 0.05). Insulin and leptin at 8 wk in the insulin group and metformin group were significantly higher, while triglyceride was significantly lower than the one in the control group (P < 0.05); triglyceride level in the insulin group was significantly higher than the one in the metformin group (P < 0.05). There was no significant difference in insulin and leptin level between the insulin group and metformin group (P > 0.05). GDM can induce the methylation of PPARGC1A of offspring rats to reduce the expression of PPARGC1A mRNA and then cause the disorder of glycolipid metabolism when the offspring rats grow up; the insulin or metformin in the treatment of pregnant rats with GDM can reduce the methylation level of PPARGC1A and thus improve the abnormal glycolipid metabolism of offspring rats.